吡嗪-喹啉 | 231-23-2

• 物质功能分类: 生物 - ELISA 试剂盒
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 吡嗪-喹啉
• 英文名称: pyrazino[2,3-f]quinoxaline
• 英文别名: 1,4,5,8-tetraazaphenanthrene；TAP
• CAS: 231-23-2
• 化学式: C₁₀H₆N₄
• mdl: MFCD00067033
• 分子量: 182.184
• InChiKey: CVSGFMWKZVZOJD-UHFFFAOYSA-N

物化性质

• 熔点：
  249-252 °C
• 沸点：
  305.57°C (rough estimate)
• 密度：
  1.3175 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2934999090
• 储存条件：
  室温

SDS

Name:	Pyrazino[2 3-f]Quinoxaline 99+% Material Safety Data Sheet
Synonym:	1,4,5,8-Tetraazaphenanthrene; TAP
CAS:	231-23-2

Section 1 - Chemical Product MSDS Name:Pyrazino[2 3-f]Quinoxaline 99+% Material Safety Data Sheet
Synonym:1,4,5,8-Tetraazaphenanthrene; TAP

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
231-23-2	Pyrazino[2,3-f]Quinoxaline	99+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 231-23-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: very slightly yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: + 250.00 - + 252.00 deg
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: 200 mg/l
Specific Gravity/Density:
Molecular Formula: C10H6N4
Molecular Weight: 182.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 231-23-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Pyrazino[2,3-f]Quinoxaline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 231-23-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 231-23-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 231-23-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吡嗪-喹啉 在 水 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以87%的产率得到pyrazino[2,3-f]quinoxaline-2,3(1H,4H)-dione
  参考文献：
  名称：

  使用超价λ为氧化喹喔啉，Tetraazaphenanthrene和六氮杂部分的直接方法3种-Iodinane化合物

  摘要：

  各种含贫电子的喹喔啉核心化合物，例如喹喔啉，1,4,5,8-四氮杂菲和1,4,5,8,9,12-六氮杂苯并菲的有效氧化反应，使用[双（三氟乙酰氧基）碘]苯的报道。使用乙腈/水溶剂混合物，可以在室温下将这些化合物以高收率或高收率转化为相应的喹喔啉二酮。这种空前的反应应能够合成可用于多个化学领域的多种化合物。

  DOI：

  10.1021/jo401872e
• 作为产物：
  描述：

  6-硝基喹喔啉 在 甲醇 、 palladium 10% on activated carbon 、 盐酸羟胺 、 sodium 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 3.83h， 生成 吡嗪-喹啉
  参考文献：
  名称：

  含杂配 1,4,5,8-四氮杂菲和双 1,2,3-三唑基的钌 (II) 配合物的光化学

  摘要：

  二亚胺金属配合物在光动力疗法 (PDT) 和光活化化学疗法 (PACT) 应用的发展中具有重要意义。特别是，已知 TAP 配体（1,4,5,8-四氮杂菲）的复合物会导致 DNA 的光诱导氧化，而基于 TAP 和三唑的复合物也已知会经历与 PACT 相关的光化学配体释放过程。杂配配合物 [Ru(TAP) n (btz) 3– n ] 2+ (btz = 1,1'-dibenzyl-4,4'-bi-1,2,3-triazolyl, n = 1 ( 1 ), 2 ( 2 )) 已被探索。在乙腈中照射后，1显示与先前观察到的 [Ru(bpy)(btz) 2 ] 2+ (bpy = 2,2'-联吡啶)类似的光化学，并生成反式-[Ru(TAP)(btz)(NCMe) 2 ] 2+ ( 5 )，已通过晶体学表征，观察配体损失中间体反式-[Ru(TAP)(κ 2 -btz)(κ 1 -btz)(NCMe)]

  DOI：

  10.1021/acs.inorgchem.1c02441

文献信息

• LIGHT INDUCED DRUG RELEASE
  申请人：Bonnet Sylvestre

  公开号：US20140148425A1

  公开（公告）日：2014-05-29

  Photosensitive compounds for use in a method of treating a disease or condition are described. The photosensitive compounds have the formula R—Y, wherein R is a ruthenium complex and Y is at least one sulphur-containing photoreleasable group, and the compounds comprise at least one ruthenium-sulphur bond; or a pharmaceutically acceptable salt, solvate, ester or amide, such that upon influence of visible or near infra-red light (400-1400 nm) in vivo, said at least one ruthenium-sulphur bond is broken, thereby generating a pharmacologically active compound.

  描述了用于治疗疾病或症状的一种方法中使用的光敏化合物。这些光敏化合物具有R—Y的化学式，其中R是一个钌配合物，Y是至少一个含硫光释放基团，这些化合物包括至少一个钌-硫键；或者是药用可接受的盐、溶剂合物、酯或酰胺，因此，在体内受到可见光或近红外光（400-1400纳米）的影响时，所述至少一个钌-硫键被断裂，从而产生一种药理活性化合物。
• NOVEL CHEMISTRY USED IN BIOSENSORS
  申请人：OHMX Corporation

  公开号：US20130112572A1

  公开（公告）日：2013-05-09

  The invention relates to novel compositions of 1,3-disubstituted ferrocenes useful for the modification of electrodes.

  这项发明涉及新型的1,3-二取代二茂铁组合物，可用于修饰电极。
• Multypodal tethers for high-density attachment of redox-active moieties to substrates
  申请人：Lindsey S. Jonathan

  公开号：US20070108438A1

  公开（公告）日：2007-05-17

  This invention provides redox-active molecules attached to polypodal (e.g., bipodal, tripodal, quadrapodal, pentapodal, etc.) tethers that can be used for attachment of the redox-active molecules to a substrate (e.g., an electrode). The tethered redox-active molecules are useful for the fabrication of memory devices.

  这项发明提供了与多脚（例如，双脚、三脚、四脚、五脚等）连接的氧化还原活性分子，可用于将这些氧化还原活性分子连接到基底（例如，电极）。连接的氧化还原活性分子可用于制作存储器件。
• A Dinuclear Osmium(II) Complex Near-Infrared Nanoscopy Probe for Nuclear DNA
  作者：Fabian Dröge、Felicity F. Noakes、Stuart A. Archer、Sreejesh Sreedharan、Ahtasham Raza、Craig C. Robertson、Sheila MacNeil、John W. Haycock、Heather Carson、Anthony J. H. M. Meijer、Carl G. W. Smythe、Jorge Bernardino de la Serna、Benjamin Dietzek-Ivanšić、Jim A. Thomas

  DOI：10.1021/jacs.1c10325

  日期：2021.12.8

  computational studies, the excited state dynamics of the new complex were dissected. These studies revealed that, although the complex has several close lying excited states, its near-infrared, NIR, emission (λmax = 780 nm) is due to a low-lying Os → TAP based 3MCLT state. Cell-based studies revealed that unlike its RuII analogue, the new complex is neither cytotoxic nor photocytotoxic. However, as it is

  为了开发光稳定的近红外细胞成像探针，报道了一种合成含有 Os(TAP) 2片段的杂配 Os II复合物的便捷途径。该方法用于合成双核 Os II复合物 [Os(TAP) 2 } 2 tpphz] 4+ (其中 tpphz = tetrapyrido[3,2-a:2′,3′-c:3″,2′ '-h:2‴,3'''-j]吩嗪和 TAP = 1,4,5,8- 四氮杂菲）。结合共振拉曼光谱和时间分辨吸收光谱以及计算研究，对新复合物的激发态动力学进行了剖析。这些研究表明，尽管该复合物有几个接近的激发态，但它的近红外、NIR、发射（λmax = 780 nm）是由于基于低位 Os → TAP 的3 MCLT 状态。基于细胞的研究表明，与它的 Ru II类似物不同，这种新的复合物既没有细胞毒性也没有光细胞毒性。然而，由于它具有高度的光稳定性和活细胞渗透性，并在生物光学窗口内显示 NIR 发光，因此其特
• Photo-reactive RuII-oligonucleotide conjugates: influence of an intercalating ligand on the inter- and intra-strand photo-ligation processes
  作者：Stéphane Le Gac、Martin Foucart、Pascal Gerbaux、Eric Defrancq、Cécile Moucheron、Andrée Kirsch - De Mesmaeker

  DOI：10.1039/c0dt00355g

  日期：——

  revealed that the similar photo-damaging efficacy of crosslinking by Ru(T) and Ru(D) is a consequence of a cascade of events with compensatory effects, originating from the different geometry of interaction of the tethered complexes. Notably, antagonistic effects are present when the complex is intercalated, the guanine oxidation step being highly favoured and the recombination of the quenching products

  已评估了两种光反应性聚氮杂芳族钌II配合物Ru（T）和Ru（D）对OligoDeoxyriboNucleotides（ODNs）的破坏作用。两种化合物都对应于已知的[Ru（TAP）2（dppz）] 2+ 复杂，但它们以不同的方式锚定到 鸟嘌呤-包含单链ODN（探针链）。这使我们能够研究束缚复合物与单链或双链之间存在的相互作用对光连接过程的影响。通过测量这些Ru-ODN及其互补序列（靶链）之间形成的双链体的解链温度，发现通过TAP配体锚定的Ru（T）通过嵌入与双链体相互作用dppz配体（几何图形上的头部），而通过dppz配体锚定的Ru（D）可能采用几何图形上的一面，而没有插入。都单股茹在不存在目标ODN的情况下，偶联物通过形成环状“ seppuuku ”光加合物（分子内光反应）而自抑制。相反，在靶链的存在下排除了该分子内光产物，并且Ru-ODN序列与后者发生光交联（分子间光反应）。两种配合物